About Zivo Bioscience
Zivo Bioscience is a publicly listed company based in Keego Harbor (United States) founded in 1983. It operates as a bioactive compounds from algal strain. It operates in the Healthcare and Agriculture sectors. Zivo Bioscience has raised $962 thousand across 20 funding rounds from investors including Health Enterprise Partners. The company has 7 employees. Zivo Bioscience offers products and services including Algal Biomass Extract and Bioactive Compounds. Its focus areas include Life Sciences, Nutraceuticals Tech, Nutraceutical Ingredients and Functional Food Ingredients. Its legal entity is Zivo Bioscience, Inc. Its competitors include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group and 5 more; 8 of its 10 listed competitors have raised funding.
Company details
Zivo Bioscience was founded in 1983 in Keego Harbor, United States, within the biotechnology sector. A patented platform is utilized for extracting bioactive molecules from algal biomass. Byproduct extracts are combined with other ingredients to produce supplements and food items, while high-value components such as nutrients and proteins are isolated. Initial market entry is targeted at nutritional products, followed by expansion into pharmaceuticals and medicinal applications.
- Headquarters Keego Harbor, United States
- Employees 7
- Stage Public
- SectorsHealthcareAgriculture
- Email••••••••
- Phone•••• ••••
- Website zivobioscience.com
- Social X
- Legal Name Zivo Bioscience, Inc.
- Annual Revenue$119.03 K (USD)-24.29as on Dec 31, 2025
- Net Profit-$9.89 M (USD)26.09as on Dec 31, 2025
- EBITDA-$9.84 M (USD)26.37as on Dec 31, 2025
- Total Equity Funding$962K (USD)
in 20 rounds
- Latest Funding Round$4M (USD), Post-IPO
Jun 2023
- Investors
- Employee Count7
Products & Services of Zivo Bioscience
Zivo Bioscience offers a comprehensive portfolio of products and services, including Algal Biomass Extract and Bioactive Compounds.
Extract for enhancing immune response in animals and human health.
Compounds supporting muscle recovery and joint health in humans.
Funding Insights of Zivo Bioscience
Zivo Bioscience has successfully raised a total of $962K across 20 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $962,000
- Total Rounds 20
- Last Round Post-IPO — $4M
- First Round $205,000
(Sep 2009)
- Investors Count 1
Latest 10 of 20 funding rounds of Zivo Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2023 | $4M | Post-IPO | – | – | – |
| Oct 2016 | $2M | Post-IPO | – | – | – |
| Mar 2014 | $100,000 | Post-IPO | – | – | – |
| Dec 2013 | $375,000 | Post-IPO | – | – | – |
| Dec 2013 | $250,000 | Post-IPO | – | – | – |
| Aug 2013 | $325,000 | Private Equity Round | – | – | – |
| Aug 2013 | $325,000 | Post-IPO | – | – | – |
| Mar 2013 | $1M | Debt – Venture | – | – | |
| Dec 2012 | $35,000 | Post-IPO | – | – | – |
| Dec 2012 | $140,000 | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Zivo Bioscience
Zivo Bioscience has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Health Enterprise Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on healthcare and information technology sectors. | 1999 | hepfund.com | New York, United States |
Investor details for Zivo Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Zivo Bioscience
7 people are tracked at Zivo Bioscience (3 in leadership, 3 in board & advisors, 1 in team); the tracked headcount is 7.
| Name | Role | Group |
|---|---|---|
Keith Marchiando | Chief Financial Officer | Leadership |
William P. Pfund | VP, Research & Development | Leadership |
Amy Elizabeth Steffek | Director, Research & Development | Leadership |
Alison A. Cornell | Director | Board & advisors |
Christopher Maggiore | Director | Board & advisors |
John B. Payne | Director | Board & advisors |
Laura Belicka | Senior Scientist | Team |
Complete people profiles for Zivo Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Zivo Bioscience
Zivo Bioscience is a publicly listed company on the OTC with ticker symbol ZIVO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Dec 2003
- Listed onOTCMKTS: ZIVO
- Listed entityZivo Bioscience, Inc.
- Exchange sectorHealth technology
- ISINUS98978N3098
- Share price$6.51 (+22.9% on the day) · 2026-10-13
- Market capitalisation$25.3M
- EPS (diluted, trailing year)$-1.41
- Volume (last session)1,912
Financials of Zivo Bioscience
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $119,030 | -$9.9M | -$9.8M |
| 2024 | $157,220 | -$13.4M | -$13.4M |
| 2023 | $27,650 | -$7.8M | -$7.3M |
| 2022 | – | -$8.8M | -$8.7M |
| 2021 | – | -$8.8M | -$8.6M |
Detailed financial statements for Zivo Bioscience
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Zivo Bioscience
4 dated milestones of Zivo Bioscience across 40 years, from founding to its latest funding, stage changes and deals.
- Founded Zivo Bioscience is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $205K.
- Funding Latest funding round, Post-IPO, of $4.0M.
Competitors of Zivo Bioscience
Zivo Bioscience has 10 listed competitors in our database, 8 of them funded. They include Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed competitors of Zivo Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Zivo Bioscience
The website of Zivo Bioscience (zivobioscience.com) receives about 3.3K visits a month.
- Monthly visits3.3K
▲ 8.6% vs previous month
Websites whose visitors overlap most with Zivo Bioscience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| nva.com | 100% | 38.9K | #595,324 | View details |
Top companies in Nutraceutical & Food-as-Medicine Platforms
10 companies that operate in the same segment as Zivo Bioscience (Nutraceutical & Food-as-Medicine Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Ayurvedic healthcare and nutritional products are provided by Kapiva. | 2016 | Bengaluru, Karnataka, India | USD 77.85 M | USD 27.35 M | 362 | |
Plant-based frozen meals are delivered via weekly subscriptions. | 2016 | London, England, United Kingdom | USD 69.9 M | USD 12.54 M | 146 | |
Therapies for metabolic health in chronic disease patients are provided. | 2014 | San Francisco, California, United States | USD 401.78 M | – | – | |
Nutritional supplements for multiple health ailments are developed. | 2005 | Mumbai, Maharashtra, India | USD 1.55 M | – | – | |
Personalized gut health solutions are provided by ZOE. | 2017 | New Castle, Pennsylvania, United States | USD 80.12 M | – | – | |
Machine learning-based bioinformatics solutions for health insights are provided. | 2016 | Los Alamos, New Mexico, United States | USD 301.57 M | – | – | |
Cellular health supplements for metabolic repair are developed and manufactured. | 2014 | New York, New York, United States | USD 66.1 M | – | – | |
Nutritional food and health supplements are provided by OZiva. | 2010 | Mumbai, Maharashtra, India | USD 17.32 M | USD 23.98 M | – | |
Low-carb products for weight loss are provided by Atkins. | 1960 | Denver, Colorado, United States | USD 15 M | – | – | |
Synbiotic supplements and fermented products for gut health are provided. | 2021 | Mumbai, Maharashtra, India | USD 20.02 M | USD 5.14 M | 88 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zivo Bioscience
Complete news archive for Zivo Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zivo Bioscience
Zivo Bioscience was founded in 1983 and raised its 1st funding round 26 years after it was founded.
Zivo Bioscience is headquartered in Keego Harbor, United States. It is registered at Keego Harbor, Michigan, United States.
Zivo Bioscience is a funded company, having raised a total of $962K across 20 funding rounds to date. The company's 1st funding round was a Post-IPO of $140K, raised on Sep 2009.
Zivo Bioscience has 7 employees.
Annual revenue of Zivo Bioscience is $119.03K as on Dec 31, 2025.
Zivo Bioscience was founded in 1983 in Keego Harbor, United States, within the biotechnology sector. A patented platform is utilized for extracting bioactive molecules from algal biomass. Byproduct extracts are combined with other ingredients to produce supplements and food items, while high-value components such as nutrients and proteins are isolated. Initial market entry is targeted at nutritional products, followed by expansion into pharmaceuticals and medicinal applications.
Zivo Bioscience's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Zivo Bioscience offers Algal Biomass Extract and Bioactive Compounds.
Yes, Zivo Bioscience is publicly traded on OTC under the ticker symbol ZIVO.
Zivo Bioscience has 1 investor. Key investors include Health Enterprise Partners.
Zivo Bioscience operates through Zivo Bioscience, Inc..